Microdosing
Microdosing — The administration of very small quantities of a compound to study its pharmacokinetic behavior without producing pharmacological effects.
What Is Microdosing?
Microdosing is the administration of sub-pharmacological doses of a peptide (typically < 100 µg or 1/100th of the pharmacological dose) to humans for early PK assessment. Microdose studies (Phase 0) can be conducted with reduced preclinical requirements, accelerating first-in-human timelines for peptide drug candidates.
Advantages
- Safety: Doses too low for pharmacological effects. Minimal risk to subjects
- PK prediction: Human PK data obtained before full Phase I
- AMS detection: ¹⁴C-labeled peptide detected by accelerator mass spectrometry at attomole levels
Frequently Asked Questions
What is Microdosing?
The administration of very small quantities of a compound to study its pharmacokinetic behavior without producing pharmacological effects.
Why is Microdosing important in peptide research?
Microdosing is a fundamental concept in research as it relates to peptide science. It directly influences experimental design, compound characterization, and the reliability of research outcomes across biochemistry and molecular biology disciplines.